DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响

doi:10.11904/j.issn.1002-3070.2024.02.003

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (2): 88-95.doi: 10.11904/j.issn.1002-3070.2024.02.003

DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响

孟凡岗, 陈飞, 甄立军

大庆龙南医院普外科(大庆 163453)

收稿日期:2023-12-26 修回日期:2024-02-08 出版日期:2024-04-28 发布日期:2024-07-12
通讯作者: 孟凡岗,E-mail:oicqyinlang1999@163.com
作者简介:孟凡岗,男,(1984-),本科,主治医师,从事乳腺癌相关的研究。

Effects of DLX2 on proliferation,migration,invasion,apoptosis of breast cancer cells and characteristics of breast cancer stem cells

MENG Fangang, CHEN Fei, ZHEN Lijun

Department of General Surgery,Longnan Hospital,Daqing 163453,China

Received:2023-12-26 Revised:2024-02-08 Online:2024-04-28 Published:2024-07-12

摘要/Abstract

摘要： 目的探索调控乳腺癌转移的关键基因,研究DLX2对乳腺癌细胞增殖、迁移、侵袭和凋亡的影响,探讨DLX2调控乳腺癌干细胞特性的作用及机制。方法构建DLX2基因敲除的乳腺癌细胞系MCF7,使用CCK-8法检测细胞增殖活力,流式细胞术检测细胞凋亡情况,Transwell实验检测细胞迁移和侵袭能力,免疫荧光检测细胞和组织中SOX4表达水平,Western blot实验检测细胞及组织中CD44和ALDH1的蛋白表达情况,TUNEL试剂盒检测组织的凋亡情况,HE染色评估肿瘤组织恶性程度。结果敲低DLX2后,细胞增殖活力减弱(P＜0.001),细胞凋亡水平增加(P＜0.001),细胞迁移、侵袭能力下降(P＜0.05)。SOX4免疫荧光检测结果显示SOX4表达被抑制。Western blot结果显示细胞干性标志物CD44和ALDH1蛋白表达水平降低(P＜0.05)。在Balb/c裸鼠乳腺癌移植瘤模型中,sh-DLX2组的肿瘤体积明显小于模型组(P＜0.001),且肿瘤生长缓慢,肿瘤体积和重量也都较模型组低(P＜0.05)。sh-DLX2组的凋亡水平较模型组高,SOX4、CD44以及ALDH1的表达与细胞水平一致,均被抑制(P＜0.05)。结论 DLX2抑制乳腺癌细胞增殖、迁移和侵袭,促进乳腺癌细胞凋亡,并通过SOX4调控乳腺癌细胞干细胞特性。

关键词: 乳腺癌, DLX2, SOX4, 肿瘤干性

Abstract: Objective The Objective of this study was to explore the key genes regulating the metastasis of breast cancer,determine the effects of DLX2 on proliferation,migration,invasion,and apoptosis of breast cancer cells,and explore the role and mechanism of DLX2 in regulating the characteristics of breast cancer stem cells. Methods A DLX2 gene knockdown breast cancer MCF7 cell line was constructed.The cell viability was detected in breast cancer cells by CCK-8 assay,apoptosis was detected in breast cancer cells by flow cytometry,cell migration and invasive abilities were detected by Transwell assay,the expression of SOX4 protein was detected by immunofluorescence(IF)in breast cancer cells and xenografts,the expression of CD44 and ALDH1 protein was detected in breast cancer cells and xenografts by Western blot,apoptosis was detected in xenografts by TUNEL assay,and the malignancy degree of tumor tissues was assessed by HE staining. Results After knocking down DLX2,the cell viability decreased(P＜0.001),apoptosis increased(P＜0.001),and cell migration and invasion abilities decreased in breast cancer cells(P＜0.05).The results of IF showed that the expression of SOX4 was inhibited.The results of Western blot showed a decrease in the expression of CD44 and ALDH1 proteins in breast cancer cells,which are cellular stemness markers(P＜0.05).In the Balb/c nude mouse breast cancer transplantation tumor model,the volume of xenografts in the sh-DLX2 group was significantly smaller than that in the model group(P＜0.001),the xenografts grew slowly,and the volume and weight of xenografts were also lower than those of the model group(P＜0.05).Apoptosis in the sh-DLX2 group was higher than that in the model group,and the expression of SOX4,CD44 and ALDH1 was consistent with the cellular level,all of which were inhibited(P＜0.05). Conclusion DLX2 inhibits proliferation,migration and invasion of breast cancer cells,promotes apoptosis of breast cancer cells,and regulates the characteristics of breast cancer stem cells through SOX4.

Key words: Breast cancer, DLX2, SOX4, Tumor stemness

中图分类号:

R737.9

孟凡岗, 陈飞, 甄立军. DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 88-95.

MENG Fangang, CHEN Fei, ZHEN Lijun. Effects of DLX2 on proliferation,migration,invasion,apoptosis of breast cancer cells and characteristics of breast cancer stem cells[J]. Journal of Practical Oncology, 2024, 38(2): 88-95.

参考文献

1 Miller KD,Nogueira L,Devasia T,et al.Cancer treatment and survivorship statistics,2022[J].CA Cancer J Clin,2022,72(5):409-436.
2 Fares J,Fares MY,Khachfe HH,et al.Molecular principles of metastasis:a hallmark of cancer revisited[J].Signal Transduct Target Ther,2020,5(1):28.
3 Lambert AW,Pattabiraman DR,Weinberg RA.Emerging biological principles of metastasis[J].Cell,2017,168(4):670-691.
4 Weigelt B,Peterse JL,Van 'T Veer LJ.Breast cancer metastasis:markers and models[J].Nat Rev Cancer,2005,5(8):591-602.
5 Su C,Zhang J,Yarden Y,et al.The key roles of cancer stem cell-derived extracellular vesicles[J].Signal Transduct Target Ther,2021,6(1):109.
6 Song K,Farzaneh M.Signaling pathways governing breast cancer stem cells behavior[J].Stem Cell Res Ther,2021,12(1):245.
7 Sun J,Ha N,Liu Z,et al.A neural crest-specific overexpression mouse model reveals the transcriptional regulatory effects of Dlx2 during maxillary process development[J].Front Physiol,2022,13:855959.
8 Sun J,Zhang J,Bian Q,et al.Effects of Dlx2 overexpression on the genes associated with the maxillary process in the early mouse embryo[J].Front Genet,2023,14:1085263.
9 Zhang J,Zhang W,Dai J,et al.Overexpression of Dlx2 enhances osteogenic differentiation of BMSCs and MC3T3-E1 cells via direct upregulation of Osteocalcin and Alp[J].Int J Oral Sci,2019,11(2):12.
10 Morini M,Astigiano S,Gitton Y,et al.Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231[J].BMC Cancer,2010,10:649.
11 Yilmaz M,Maass D,Tiwari N,et al.Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis[J].Embo J,2011,30(21):4489-4499.
12 Tang P,Huang H,Chang J,et al.Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma[J].World J Gastroenterol,2013,19(17):2697-2703.
13 Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.
14 Gao X,Sishc BJ,Nelson CB,et al.Radiation-induced reprogramming of pre-senescent mammary epithelial cells enriches putative CD44(+)/CD24(-/low)stem cell phenotype[J].Front Oncol,2016,6:138.
15 Panigoro SS,Kurnia D,Kurnia A,et al.ALDH1 cancer stem cell marker as a prognostic factor in triple-negative breast cancer[J].Int J Surg Oncol,2020,2020:7863243.

[1]	黑龙江省医学会乳腺肿瘤学组. 黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)[J]. 实用肿瘤学杂志, 2024, 38(2): 71-78.
[2]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.
[3]	谢俊岭. 活化白细胞黏附分子在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 45-49.
[4]	冯楚然, 曹剑钊, 陈子印, 张大昕, 鲁海玲. 乳腺癌放射性心脏损伤及其预防措施的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 513-518.
[5]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[6]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[7]	王新萍, 张自云, 王学东. 非编码RNA在乳腺癌化疗耐药中作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 454-458.
[8]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[9]	陈飞, 王颖, 曾传琴. B7-H4在乳腺癌组织中的表达及其与患者新辅助化疗后腋窝淋巴结转移的相关性分析[J]. 实用肿瘤学杂志, 2023, 37(4): 360-366.
[10]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[11]	马艳玲, 钱立庭, 魏东华, 尹惠萍, 张娟, 张小鹏. 2014—2017年安徽省合肥市城市乳腺癌高危人群筛查率及其影响因素分析[J]. 实用肿瘤学杂志, 2023, 37(3): 200-206.
[12]	隋世尧, 郑玮, 杨子涵, 庞达. lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡[J]. 实用肿瘤学杂志, 2023, 37(3): 215-223.
[13]	张庆怀, 韩阿蒙, 杨森, 李秀梅, 赵健鑫, 张彦秋. 乳腺癌患者保乳术后五种放疗技术的疗效比较研究[J]. 实用肿瘤学杂志, 2023, 37(3): 224-229.
[14]	杨帅, 王新恒, 吴佳乐, 付子彤, 魏博, 杨灵冰, 许守平. 单细胞测序技术在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 287-292.
[15]	张馨, 吴羡美, 李虹, 刘晓舟, 孔德文, 陈琢. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担[J]. 实用肿瘤学杂志, 2023, 37(2): 107-111.

DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响

Effects of DLX2 on proliferation,migration,invasion,apoptosis of breast cancer cells and characteristics of breast cancer stem cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价